Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 10/20 | 0.50 |
| ▸ | MMP9 | P14780 | 7/20 | 0.50 |
| ▸ | MMP13 | P45452 | 7/20 | 0.50 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.50 |
| ▸ | KDR | P35968 | 5/20 | 0.40 |
| ▸ | BRAF | P15056 | 3/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | RAF1 | P04049 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12132181 | 0.82 | KDR (0.51) | KDRBRAF | |
| SCHEMBL1352582 | 0.72 | KDR (0.46) | MMP1MMP9MMP13ADAM17KDR | |
| SCHEMBL1353035 | 0.72 | CSF1R (0.46) | — | |
| SCHEMBL12132186 | 0.68 | MELK (0.42) | MMP1MMP9MMP13KDM4E | |
| SCHEMBL7004353 | 0.68 | MMP13 (0.78) | MMP1MMP9MMP13ADAM17 | |
| Hydrochloric Acid SCHEMBL7007676 | 0.67 | MMP13 (0.77) | MMP1MMP9MMP13ADAM17 | |
| SCHEMBL2599833 | 0.67 | TERT (0.40) | — | |
| SCHEMBL2599628 | 0.67 | PDE4B (0.49) | MMP1MMP9MMP13ADAM17BRAF | |
| SCHEMBL15184747 | 0.63 | NUDT1 (0.51) | — | |
| SCHEMBL15184757 | 0.63 | TACR1 (0.42) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513421-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513421-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513421-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20110288117-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110288117-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288117-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC5 | MMP1 179/4885MMP9 599/4885MMP13 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.